安罗替尼治疗晚期非小细胞肺癌的疗效观察

Curative Effect Observation of Anlotinib in Treatment of Advanced Non-Small Cell Lung Cancer

目的观察安罗替尼应用在晚期非小细胞肺癌(NSCLC)治疗中的安全性。方法将2020年6月—2021年6月本院收治的21例晚期NSCLC患者设为观察组,对其采取安罗替尼三线治疗;将同期收治的另外21例晚期NSCLC患者设为对照组,对其进行吉西他滨单药方案治疗;观察两组治疗效果,并随访6个月,观察两组预后情况。结果观察组临床疗效为19.05%,对照组为4.76%(P<0.05);观察组疾病控制率为90.48%,对照组为61.90%(P<0.05);两组患者治疗后各项不良反应的发生率对比无显著差异(P>0.05);观察组6个月的PFS率和8个月的OS率明显比对照组更高,组间差异具有统计学意义(P<0.05)。结论在晚期NSCLC治疗中,与使用吉西他滨比较,使用安罗替尼治疗效果更佳,病人预后效果相对较好。

Objective To observe safety of anlotinib in treatment of advanced non-small cell lung cancer(NSCLC).Methods The paper chose 21 patients with advanced NSCLC from June 2020 to June 2021 as observation group,treated with third line treatment with anlotinib,and 21 advanced NSCLC patients at the same time as control group,with gemcitabine monotherapy.Curative effect between two groups was observed,followed up for 6 months,prognosis between two groups was observed.Results Total effective rate of clinical effect after treatment in observation group was 19.05%,that in control group was 4.76%.Disease control rate in observation group was 90.48%,that in control group was 61.90%.Difference between groups showed P<0.05.Comparison of incidence of various adverse reactions between two groups after treatment showed P>0.05.PFS rate after 6 months and OS rate after 8 months in observation group was significantly higher than control group,difference between groups showed P<0.05.Conclusion Anlotinib can achieve better curative effect and relatively better prognosis for patients with advanced NSCLC than gemcitabine only.